



PRIOR AUTHORIZATION REQUEST FORM

EOC ID:

Stelara (Ustekinumab)

Phone: 800-728-7947

Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Supervising Physician:	
Date of Birth:	Fax:	Phone:
Group Number:	Office Contact:	
Address:	NPI:	State Lic ID:
City, State ZIP:	Address:	
Primary Phone:	City, State ZIP:	
	Specialty/facility name (if applicable):	

Drug Name and Strength:

Directions / SIG:

Please attach any pertinent medical history or information for this patient that may support approval. Please answer the following questions and sign.

<p>Q1. Select the regimen being requested.</p> <p><input type="checkbox"/> Stelara 90 mg SQ every 12 weeks</p> <p><input type="checkbox"/> Stelara 45 mg SQ every 12 weeks</p> <p><input type="checkbox"/> IV Induction: 260 mg, 390 mg, or 520 mg (Please specify and provide current weight)</p> <p><input type="checkbox"/> Other</p>
<p>Q2. What diagnosis is this drug being prescribed for (select ALL that apply)?</p> <p><input type="checkbox"/> Plaque psoriasis <input type="checkbox"/> Psoriatic arthritis <input type="checkbox"/> Crohn's Disease <input type="checkbox"/> Other</p>
<p>Q3. Provide ICD code(s) for diagnosis.</p>
<p>Q4. What is the prescriber's specialty?</p> <p><input type="checkbox"/> Dermatologist <input type="checkbox"/> Rheumatologist <input type="checkbox"/> Gastroenterology <input type="checkbox"/> Other</p>
<p>Q5. Select ALL of the following that apply to the patient:</p> <p><input type="checkbox"/> Moderate to severe PLAQUE PSORIASIS affecting GREATER THAN 5% of body surface area (BSA)</p> <p><input type="checkbox"/> Moderate to severe PLAQUE PSORIASIS affecting CRUCIAL BODY AREAS such as hands, feet, face, or genitals</p> <p><input type="checkbox"/> PSORIATIC ARTHRITIS with documented SPINAL INVOLVEMENT (psoriatic spondylitis)</p>



PRIOR AUTHORIZATION REQUEST FORM

EOC ID:

Stelara (Ustekinumab)

Phone: 800-728-7947

Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

Patient Name:	Prescriber Name:
	Supervising Physician:
<input type="checkbox"/> None of the above	
Q6. Has the patient failed at least TWO TOPICAL treatments [including but not limited to corticosteroids, Vitamin D analogues, Vitamin D analogue/corticosteroid combinations, Tazorac® (tazarotene)]?	
<input type="checkbox"/> Yes	
<input type="checkbox"/> No	
<input type="checkbox"/> N/A - Patient does not have plaque psoriasis	
Q7. Has the patient failed, or does the patient have a contraindication to phototherapy (UVB or PUVA)?	
<input type="checkbox"/> Yes	
<input type="checkbox"/> No	
<input type="checkbox"/> N/A - Patient does not have plaque psoriasis	
Q8. Select ALL of the following that apply to this patient:	
<input type="checkbox"/> For psoriasis, failed AT LEAST ONE of the following: methotrexate, cyclosporine, acitretin, leflunomide, sulfasalazine, tacrolimus	
<input type="checkbox"/> For psoriasis, contraindication to methotrexate, cyclosporine, acitretin, leflunomide, sulfasalazine, or tacrolimus	
<input type="checkbox"/> For psoriatic arthritis, failed methotrexate	
<input type="checkbox"/> For psoriatic arthritis, contraindication to methotrexate	
<input type="checkbox"/> For psoriatic arthritis, failed AT LEAST ONE of the following: hydroxychloroquine, sulfasalazine, leflunomide, azathioprine, D-penicillamine, gold (oral or IM), minocycline, cyclosporine, staphylococcal protein A immunoabsorption	
<input type="checkbox"/> For psoriatic arthritis, contraindication to hydroxychloroquine, sulfasalazine, leflunomide, azathioprine, D-penicillamine, gold (oral or IM), minocycline, cyclosporine, AND staphylococcal protein A immunoabsorption	
<input type="checkbox"/> For Crohn's Disease, failure of or contraindication to an anti-inflammatory drug (e.g. mesalamine, sulfasalazine), corticosteroid, or an immunosuppressive	
Q9. Is the patient a NEW START to Stelara?	
<input type="checkbox"/> Yes	
<input type="checkbox"/> No	
Q10. Select the agents the patient has failed	
<input type="checkbox"/> Enbrel	
<input type="checkbox"/> Humira	
<input type="checkbox"/> Other (please specify)	
<input type="checkbox"/> None	
Q11. Has the patient failed Cosentyx?	



PRIOR AUTHORIZATION REQUEST FORM

EOC ID:

Stelara (Ustekinumab)

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name: Prescriber Name: Supervising Physician:

Q12. What is the patient's weight? Q13. Additional Comments

Prescriber Signature Date

Expedited/Urgent - By checking this box and signing above, I certify that applying the standard review timeframe may seriously jeopardize the life or health of the enrollee or the enrollee's ability to regain maximum function

Lack of the necessary documentation may result in a medical necessity denial. Requesting providers may speak to the SWHP medical director at 1-888-316-7947 regarding the case to have an opportunity to help impact the decision on a request before coverage has been decided.

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document